Noubar Afeyan is Director at Moderna, Inc. (MRNA). They have made 56 open-market trades across 8 companies since 2006, most recently 2026-05-21.
CIK 0001222012
5 open-market purchases totalling $92.4M since 2013, against 51 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GENB | 15,264,724 | $184.2M |
| AGIO | 1,930,369 | $60.6M |
| TMDX | 268,736 | $19.0M |
| MCRB | 5,875,711 | $14.5M |
| EDIT | 3,656,564 | $8.6M |
| SANA | 2,727,272 | $6.2M |
| CNCE | 563,482 | $4.7M |
| FHTX | 1,814,915 | $3.4M |
| RUBY | 15,393,593 | $2.7M |
| EBIO | 272,677 | $897K |
| MRNA | 3,924 | $854K |
| KLDO | 947,111 | $275K |
| BIND | 1,562,616 | — |
| BGMD | 93,572 | — |
| Total | $305.9M |
Shares reported on the most recent Form 4, priced at the 2026-05-22 close. 2 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MRNA | SELL | 2026-05-21 | 2026-05-22 | $46.84 | $434K | +8.6% | +24.9% | +180.3% |
| GENB | BUY | 2026-03-02 | 2026-03-02 | $16.00 | $25.0M | +7.4% | +8.1% | +5.4% |
| MRNA | SELL | 2025-12-11 | 2025-12-15 | $29.49 | $1.4M | +4.3% | +35.7% | +78.4% |
| MRNA | SELL · 10b5-1 | 2024-07-31 | 2024-08-02 | $119.96 | $3.6M | +2.3% | -9.2% | -32.4% |
| MRNA | SELL · 10b5-1 | 2024-07-24 | 2024-07-26 | $117.78 | $2.9M | -33.5% | -33.4% | -56.9% |
| MRNA | SELL · 10b5-1 | 2024-07-17 | 2024-07-19 | $122.90 | $3.0M | -2.7% | -26.6% | -55.3% |
| MRNA | SELL · 10b5-1 | 2024-07-10 | 2024-07-12 | $116.84 | $3.0M | -2.4% | -32.9% | -53.1% |
| MRNA | SELL · 10b5-1 | 2024-06-26 | 2024-06-28 | $127.25 | $2.7M | +4.9% | +4.4% | -45.4% |
| MRNA | SELL · 10b5-1 | 2024-06-18 | 2024-06-21 | $133.63 | $3.7M | -13.8% | -9.0% | -49.5% |
| MRNA | SELL · 10b5-1 | 2024-06-12 | 2024-06-14 | $147.29 | $4.3M | -12.3% | -12.1% | -49.6% |
| MRNA | SELL | 2024-06-11 | 2024-06-11 | $148.31 | $59.2M | -8.7% | -18.1% | -48.9% |
| MRNA | SELL · 10b5-1 | 2024-06-05 | 2024-06-07 | $151.70 | $3.9M | -11.3% | -23.1% | -51.5% |
| MRNA | SELL · 10b5-1 | 2024-05-29 | 2024-05-31 | $145.33 | $4.9M | +5.7% | -17.0% | -44.5% |
| MRNA | SELL · 10b5-1 | 2024-05-22 | 2024-05-24 | $158.34 | $3.7M | -4.3% | -15.2% | -49.9% |
| MRNA | SELL · 10b5-1 | 2024-05-15 | 2024-05-17 | $127.28 | $3.5M | +13.9% | +3.7% | -34.9% |
| MRNA | SELL · 10b5-1 | 2024-05-08 | 2024-05-10 | $121.78 | $3.4M | +36.7% | +24.4% | -29.4% |
| MRNA | SELL · 10b5-1 | 2024-05-01 | 2024-05-03 | $110.76 | $3.1M | +3.2% | +18.3% | -24.7% |
| MRNA | SELL · 10b5-1 | 2024-04-24 | 2024-04-26 | $108.26 | $3.1M | +12.1% | +40.8% | +10.7% |
| MRNA | SELL · 10b5-1 | 2024-04-17 | 2024-04-19 | $103.37 | $3.1M | +8.4% | +37.2% | +18.0% |
| MRNA | SELL · 10b5-1 | 2024-04-10 | 2024-04-12 | $107.09 | $3.2M | +3.6% | +19.7% | +16.9% |
| MRNA | SELL · 10b5-1 | 2024-04-03 | 2024-04-05 | $101.58 | $2.7M | +1.1% | +19.4% | +15.7% |
| MRNA | SELL · 10b5-1 | 2024-03-27 | 2024-03-29 | $109.16 | $2.8M | +0.8% | +5.0% | +14.0% |
| MRNA | SELL · 10b5-1 | 2024-03-20 | 2024-03-22 | $102.39 | $3.1M | -3.5% | -1.5% | +26.8% |
| MRNA | SELL · 10b5-1 | 2024-03-13 | 2024-03-15 | $108.57 | $2.9M | +5.3% | -1.1% | +38.3% |
| MRNA | SELL · 10b5-1 | 2023-11-01 | 2023-11-03 | $76.00 | $760K | -2.2% | +2.3% | +26.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.